Temocillin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Temocillin
DrugBank Accession Number
DB12343
Background

Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 414.45
Monoisotopic: 414.055543276
Chemical Formula
C16H18N2O7S2
Synonyms
  • Temocillin
  • temocillina

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcemetacinAcemetacin may decrease the excretion rate of Temocillin which could result in a higher serum level.
AcenocoumarolTemocillin may increase the anticoagulant activities of Acenocoumarol.
AmikacinThe serum concentration of Amikacin can be decreased when it is combined with Temocillin.
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Temocillin.
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Temocillin.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Temocillin.
CapreomycinThe serum concentration of Capreomycin can be decreased when it is combined with Temocillin.
CinoxacinThe serum concentration of Cinoxacin can be increased when it is combined with Temocillin.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Temocillin.
CisatracuriumThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Temocillin.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Temocillin Sodium96IIP39ODH61545-06-0MRGCZDWBFFUEES-CWBCWDDISA-L

Categories

ATC Codes
J01CR50 — Combinations of penicillinsJ01CA17 — Temocillin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Penicillins / N-acyl-alpha amino acids and derivatives / 1,3-dicarbonyl compounds / Dicarboxylic acids and derivatives / Thiophenes / Thiazolidines / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Azetidines
show 8 more
Substituents
1,3-dicarbonyl compound / Alpha-amino acid or derivatives / Alpha-dipeptide / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Beta-lactam / Carbonyl group / Carboxamide group / Carboxylic acid
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
penicillin (CHEBI:51817)
Affected organisms
Not Available

Chemical Identifiers

UNII
03QB156W6I
CAS number
66148-78-5
InChI Key
BVCKFLJARNKCSS-DWPRYXJFSA-N
InChI
InChI=1S/C16H18N2O7S2/c1-15(2)9(12(22)23)18-13(24)16(25-3,14(18)27-15)17-10(19)8(11(20)21)7-4-5-26-6-7/h4-6,8-9,14H,1-3H3,(H,17,19)(H,20,21)(H,22,23)/t8?,9-,14+,16-/m0/s1
IUPAC Name
(2S,5R,6S)-6-[2-carboxy-2-(thiophen-3-yl)acetamido]-6-methoxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
SMILES
CO[C@]1(NC(=O)C(C(O)=O)C2=CSC=C2)[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O

References

General References
Not Available
PubChem Compound
171758
PubChem Substance
347828601
ChemSpider
150149
RxNav
37775
ChEBI
51817
ChEMBL
CHEMBL1276310
Wikipedia
Temocillin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentGram-Negative Bacterial Infections / Renal Failure Chronic Requiring Hemodialysis1
4CompletedTreatmentUrinary Tract Infection1
4Unknown StatusOtherInfection / Liver Dysfunction / Urinary Tract Infection1
4Unknown StatusTreatmentUrinary Tract Infection1
4WithdrawnTreatmentUrinary Tract Infection1
3CompletedTreatmentUrinary Tract Infection1
3RecruitingTreatmentBacteremia1
Not AvailableNot Yet RecruitingOtherAntibacterial Agents / Bacterial Infections / Drug Monitoring / Infection / Pharmacokinetics / Temocillin1
Not AvailableRecruitingOtherAnti-Bacterial Agents / Bacterial Infections / Drug Monitoring / Infection / Pharmacokinetics / Respiratory Tract Infections (RTI)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.102 mg/mLALOGPS
logP1.13ALOGPS
logP1.2ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)3.1ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area133.24 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity94.22 m3·mol-1ChemAxon
Polarizability38.91 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 22:01 / Updated on February 21, 2021 18:53